Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.
Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.
The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.
Makers of PharmASSIST, Innovation has announced that John Courtney will join the company’s sales team as director of sales. In this role, Courtney will lead all of Innovation’s sales activity for the western and central United States for hospital outpatient and federal health care.
Automation and Technology
Nearly 20 million Americans have trouble reading or understanding a prescription label. Officials at En-Vision America say they have a solution.